193 related articles for article (PubMed ID: 32012241)
1. Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
Maynard H; Stadler ZK; Berger MF; Solit DB; Ly M; Lowery MA; Mandelker D; Zhang L; Jordan E; El Dika I; Kemel Y; Ladanyi M; Robson ME; O'Reilly EM; Abou-Alfa GK
Cancer; 2020 Jan; 126(9):1995-2002. PubMed ID: 32012241
[TBL] [Abstract][Full Text] [Related]
2. Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes.
Wong W; Lowery MA; Berger MF; Kemel Y; Taylor B; Zehir A; Srinivasan P; Bandlamudi C; Chou J; Capanu M; Varghese A; Yu KH; Iacobuzio-Donahue CA; Shia J; Klimstra DS; Jarnagin WR; Stadler ZK; O'Reilly EM
Cancer; 2019 May; 125(9):1441-1448. PubMed ID: 30620386
[TBL] [Abstract][Full Text] [Related]
3. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
5. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer.
Ku GY; Kemel Y; Maron SB; Chou JF; Ravichandran V; Shameer Z; Maio A; Won ES; Kelsen DP; Ilson DH; Capanu M; Strong VE; Molena D; Sihag S; Jones DR; Coit DG; Tuvy Y; Cowie K; Solit DB; Schultz N; Hechtman JF; Offit K; Joseph V; Mandelker D; Janjigian YY; Stadler ZK
JAMA Netw Open; 2021 Jul; 4(7):e2114753. PubMed ID: 34251444
[TBL] [Abstract][Full Text] [Related]
7. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
8. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
[TBL] [Abstract][Full Text] [Related]
11. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Lowery MA; Wong W; Jordan EJ; Lee JW; Kemel Y; Vijai J; Mandelker D; Zehir A; Capanu M; Salo-Mullen E; Arnold AG; Yu KH; Varghese AM; Kelsen DP; Brenner R; Kaufmann E; Ravichandran V; Mukherjee S; Berger MF; Hyman DM; Klimstra DS; Abou-Alfa GK; Tjan C; Covington C; Maynard H; Allen PJ; Askan G; Leach SD; Iacobuzio-Donahue CA; Robson ME; Offit K; Stadler ZK; O'Reilly EM
J Natl Cancer Inst; 2018 Oct; 110(10):1067-1074. PubMed ID: 29506128
[TBL] [Abstract][Full Text] [Related]
12. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
Okawa Y; Iwasaki Y; Johnson TA; Ebata N; Inai C; Endo M; Maejima K; Sasagawa S; Fujita M; Matsuda K; Murakami Y; Nakamura T; Hirano S; Momozawa Y; Nakagawa H
J Hepatol; 2023 Feb; 78(2):333-342. PubMed ID: 36243179
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.
Wu J; Wang H; Ricketts CJ; Yang Y; Merino MJ; Zhang H; Shi G; Gan H; Linehan WM; Zhu Y; Ye D
Cancer; 2019 Apr; 125(7):1060-1069. PubMed ID: 30548481
[TBL] [Abstract][Full Text] [Related]
14. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
15. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
16. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.
Ahn DH; Bekaii-Saab T
Chin Clin Oncol; 2020 Feb; 9(1):6. PubMed ID: 32075397
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
[TBL] [Abstract][Full Text] [Related]
18. Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study.
Nassar A; Zekri AN; Kamel MM; Elberry MH; Lotfy MM; Seadawy MG; Hassan ZK; Soliman HK; Lymona AM; Youssef ASE
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672847
[TBL] [Abstract][Full Text] [Related]
19. Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
Li G; Guo X; Tang L; Chen M; Luo X; Peng L; Xu X; Wang S; Xiao Z; Yi W; Dai L; Wang J
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2011-2024. PubMed ID: 28664449
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]